NOVAVAX INC
NVAX · XNASCIK 1000694fmd_1507CZ4EFZKT3E1FG285X34405Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 15 | 31 | 34 | 19 | 476 | 1,146 | 1,982 | 984 | 682 | 1,123 |
| Cost of revenue | – | – | – | – | 0 | 0 | 903 | 344 | 203 | 73 |
| Gross profit | – | – | – | – | 476 | 1,146 | 1,079 | 640 | 479 | 1,050 |
| Research and development | 238 | 168 | 174 | 114 | 747 | 2,535 | 1,235 | 738 | 391 | 342 |
| Selling, general and administrative | – | – | – | – | – | – | 489 | 469 | 337 | 157 |
| Operating income | (269) | (172) | (174) | (121) | (417) | (1,687) | (645) | (567) | (249) | 453 |
| Interest expense | 13 | 14 | 14 | 14 | 15 | 21 | 20 | 14 | 20 | 23 |
| Interest and investment income | – | – | – | – | – | – | – | 20 | 37 | 30 |
| Other non-operating income (expense) | (0) | 0 | 0 | (0) | 14 | (7) | 11 | 38 | 40 | 41 |
| Income before taxes | – | – | – | (133) | (418) | (1,715) | (654) | (543) | (177) | 442 |
| Income tax expense | – | – | – | 0 | 0 | 29 | 4 | 2 | 11 | 2 |
| Net income from continuing operations | – | – | – | (133) | (418) | (1,744) | (658) | (545) | (187) | 440 |
| Net income | (280) | (184) | (185) | (133) | (418) | (1,744) | (658) | (545) | (187) | 440 |
| Net income to common shareholders | – | – | – | – | – | – | – | (545) | (187) | 440 |